Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Enteral Tranexamic Acid in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Critically ill patients admitted to ICU within 48 hours of onset of illness~* Patients with feeding tubes (e.g., orogastric, nasogastric, PEG, etc.)~Exclusion Criteria:~* primary admitting diagnosis of cancer~* primary admitting diagnosis of acute congestive heart failure~* primary admitting diagnosis of chronic obstructive pulmonary disease (COPD)~* primary admitting diagnosis of acute myocardial infarction or unstable cardiac arrythmia~* primary admitting diagnosis of amyotrophic lateral sclerosis (ALS) or other non-infectious disease~* primary admitting diagnosis of post-operative neurosurgical procedure~* known hypersensitivity to tranexamic acid~* acquired disturbances of color vision~* hematuria cause by disease of the renal parenchyma~* active thromboembolic disease such as deep venous thrombosis or pulmonary embolism~* patients with known clotting disorders or other known bleeding disorders~* recent (within 3 months) or active cerebrovascular bleed~* pregnancy~* inability to take study medicine (i.e., ileus with \> 500ml stomach residuals, NPO status)~* patients excluded at the discretion of the treating physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: EXPERIMENTAL): Study group receives enteral tranexamic acid in normal saline in addition to usual care.
- Control group (Type: PLACEBO_COMPARATOR): Control group receives vehicle (normal saline) without study drug and usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).